216 related articles for article (PubMed ID: 33191086)
41. Synthesis and antitumor activity of novel steroidal imidazolium salt derivatives.
Deng G; Zhou B; Wang J; Chen Z; Gong L; Gong Y; Wu D; Li Y; Zhang H; Yang X
Eur J Med Chem; 2019 Apr; 168():232-252. PubMed ID: 30822712
[TBL] [Abstract][Full Text] [Related]
42. Discovery of 3-(((9H-purin-6-yl)amino)methyl)-4,6-dimethylpyridin-2(1H)-one derivatives as novel tubulin polymerization inhibitors for treatment of cancer.
Zhang Q; Hu X; Wan G; Wang J; Li L; Wu X; Liu Z; Yu L
Eur J Med Chem; 2019 Dec; 184():111728. PubMed ID: 31610375
[TBL] [Abstract][Full Text] [Related]
43. Design, synthesis and biological evaluation of novel benzimidazole-2-substituted phenyl or pyridine propyl ketene derivatives as antitumour agents.
Wu LT; Jiang Z; Shen JJ; Yi H; Zhan YC; Sha MQ; Wang Z; Xue ST; Li ZR
Eur J Med Chem; 2016 May; 114():328-36. PubMed ID: 27017265
[TBL] [Abstract][Full Text] [Related]
44. Design, synthesis and biological evaluation of 7-methylimidazo[1,5-a]pyrazin-8(7H)-one derivatives as BRD4 inhibitors.
Zhao L; Yang Y; Guo Y; Yang L; Zhang J; Zhou J; Zhang H
Bioorg Med Chem; 2017 Apr; 25(8):2482-2490. PubMed ID: 28314513
[TBL] [Abstract][Full Text] [Related]
45. Synthesis and biological evaluation of novel 1,6-diaryl pyridin-2(1H)-one analogs.
Chen T; Luo Y; Hu Y; Yang B; Lu W
Eur J Med Chem; 2013 Jun; 64():613-20. PubMed ID: 23708235
[TBL] [Abstract][Full Text] [Related]
46. Synthesis, and evaluation of in vitro and in vivo anticancer activity of 14-substituted oridonin analogs: A novel and potent cell cycle arrest and apoptosis inducer through the p53-MDM2 pathway.
Shen QK; Deng H; Wang SB; Tian YS; Quan ZS
Eur J Med Chem; 2019 Jul; 173():15-31. PubMed ID: 30981113
[TBL] [Abstract][Full Text] [Related]
47. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
[TBL] [Abstract][Full Text] [Related]
48. Structure optimization, synthesis, and biological evaluation of 6-(2-amino-1H-benzo[d]imidazole-6-yl)-quinazolin-4(3H)-one derivatives as potential multi-targeted anticancer agents via Aurora A/ PI3K/BRD4 inhibition.
Fan Y; Luo F; Su M; Li Q; Zhong T; Xiong L; Li M; Yuan M; Wang D
Bioorg Chem; 2023 Mar; 132():106352. PubMed ID: 36682147
[TBL] [Abstract][Full Text] [Related]
49. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
Cheng C; Yun F; He J; Ullah S; Yuan Q
Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060
[TBL] [Abstract][Full Text] [Related]
50. 2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study.
AboulWafa OM; Daabees HMG; Badawi WA
Bioorg Chem; 2020 Jun; 99():103798. PubMed ID: 32247112
[TBL] [Abstract][Full Text] [Related]
51. New indenopyrazole linked oxadiazole conjugates as anti-pancreatic cancer agents: Design, synthesis, in silico studies including 3D-QSAR analysis.
Khan I; Ganapathi T; Rehman MM; Shareef MA; Kumar CG; Kamal A
Bioorg Med Chem Lett; 2021 Jul; 44():128094. PubMed ID: 33964437
[TBL] [Abstract][Full Text] [Related]
52. An optimized BRD4 inhibitor effectively eliminates NF-κB-driven triple-negative breast cancer cells.
Yang GJ; Song YQ; Wang W; Han QB; Ma DL; Leung CH
Bioorg Chem; 2021 Sep; 114():105158. PubMed ID: 34378541
[TBL] [Abstract][Full Text] [Related]
53. Discovery of a Small-Molecule Bromodomain-Containing Protein 4 (BRD4) Inhibitor That Induces AMP-Activated Protein Kinase-Modulated Autophagy-Associated Cell Death in Breast Cancer.
Ouyang L; Zhang L; Liu J; Fu L; Yao D; Zhao Y; Zhang S; Wang G; He G; Liu B
J Med Chem; 2017 Dec; 60(24):9990-10012. PubMed ID: 29172540
[TBL] [Abstract][Full Text] [Related]
54. Design, synthesis, and evaluation of novel coumarin-dithiocarbamate derivatives (IDs) as anti-colorectal cancer agents.
Zhu H; Ying S; Zhou B; Hu X; Liang X; Li W; Wang D; Jin H; Pan Y
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):593-604. PubMed ID: 33557648
[TBL] [Abstract][Full Text] [Related]
55. Design, synthesis, and biological evaluation of novel benzodiazepine derivatives as anticancer agents through inhibition of tubulin polymerization in vitro and in vivo.
Pang Y; Lin H; Ou C; Cao Y; An B; Yan J; Li X
Eur J Med Chem; 2019 Nov; 182():111670. PubMed ID: 31499359
[TBL] [Abstract][Full Text] [Related]
56. Design, synthesis and biological evaluation of novel ferrocene-pyrazole derivatives containing nitric oxide donors as COX-2 inhibitors for cancer therapy.
Ren SZ; Wang ZC; Zhu D; Zhu XH; Shen FQ; Wu SY; Chen JJ; Xu C; Zhu HL
Eur J Med Chem; 2018 Sep; 157():909-924. PubMed ID: 30149323
[TBL] [Abstract][Full Text] [Related]
57. Design, synthesis and biological evaluation of tetrahydroquinoline-based reversible LSD1 inhibitors.
Wang X; Zhang C; Zhang X; Yan J; Wang J; Jiang Q; Zhao L; Zhao D; Cheng M
Eur J Med Chem; 2020 May; 194():112243. PubMed ID: 32229389
[TBL] [Abstract][Full Text] [Related]
58. Design and synthesis of novel 2'-hydroxy group substituted 2-pyridone derivatives as anticancer agents.
Lv Z; Zhang Y; Zhang M; Chen H; Sun Z; Geng D; Niu C; Li K
Eur J Med Chem; 2013 Sep; 67():447-53. PubMed ID: 23920246
[TBL] [Abstract][Full Text] [Related]
59. Design, Synthesis, and Biological Evaluation of a Potent Dual EZH2-BRD4 Inhibitor for the Treatment of Some Solid Tumors.
Huang N; Liao P; Zuo Y; Zhang L; Jiang R
J Med Chem; 2023 Feb; 66(4):2646-2662. PubMed ID: 36774555
[TBL] [Abstract][Full Text] [Related]
60. Synthesis and antitumor activities evaluation of m-(4-morpholinoquinazolin-2-yl)benzamides in vitro and in vivo.
Wang XM; Xin MH; Xu J; Kang BR; Li Y; Lu SM; Zhang SQ
Eur J Med Chem; 2015; 96():382-95. PubMed ID: 25911625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
